Medivir subsidiary BioPhausia AB sells generics business

29-Aug-2011 - Sweden

Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m. The staff of BMM Pharma will not transfer in the acquisition.

“This deal is a natural last step in the concentration and focus of BioPhausia’s business, which began about a year ago. We will now be focusing on the ongoing commercial development of our Proprietary Products and Parallel Imported Products” commented Maris Hartmanis, CEO of BioPhausia AB.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances